Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 8/20 | 0.63 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23523838 | 1.00 | XDH (0.63) | XDHS1PR1CYP2D6TRPM8 | |
| SCHEMBL23523942 | 0.82 | XDH (0.67) | XDHS1PR1CYP2D6 | |
| SCHEMBL23523734 | 0.81 | XDH (0.63) | XDHS1PR1CYP2D6 | |
| SCHEMBL23524062 | 0.81 | XDH (0.61) | XDHS1PR1CYP2D6 | |
| SCHEMBL30355422 | 0.81 | XDH (0.65) | XDHS1PR1CYP2D6 | |
| SCHEMBL23523851 | 0.81 | XDH (0.65) | XDHS1PR1CYP2D6 | |
| SCHEMBL30355410 | 0.81 | XDH (0.61) | XDHS1PR1CYP2D6 | |
| SCHEMBL2409319 | 0.80 | XDH (0.71) | XDHS1PR1CYP2D6 | |
| SCHEMBL23524370 | 0.79 | MAPT (0.44) | XDHTRPM8 | |
| SCHEMBL30355694 | 0.79 | MAPT (0.44) | XDHTRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | XDH 4416/4885S1PR1 1/4885CYP2D6 4598/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | XDH 3320/4885S1PR1 1/4885CYP2D6 4320/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | XDH 4416/4885S1PR1 1/4885CYP2D6 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.